What is the typical structure of a pharma M&A deal?

Most large pharma acquisitions include an upfront cash payment plus contingent value rights (CVRs) tied to regulatory or commercial milestones. Deal multiples typically range from 4-8x projected peak revenue for commercial-stage assets, and 15-30x for pre-revenue pipeline compounds with breakthrough potential.